Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001169
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Clinical Investigation of Infections Due to Leishmanial Parasites
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Clinical Investigation of Infections Due to Leishmanial Parasites
Status:
COMPLETED
Status Verified Date:
2000-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Mechanisms of host immune response to intracellular protozoa will be investigated in patients with naturally acquired infection employing a variety of in-vitro techniques Both non-specific and antigen-specific humoral and cellular immune responses will be assessed Parasites will be isolated from patients cultivated in-vitro and characterized Responses to chemotherapy will be assessed parasitologically immunologically and clinically
Detailed Description:
The main purpose of this protocol is to permit us to see patients who are referred to us for diagnosis and treatment of known or suspected leishmaniasis from the Peace Corps Smithsonian Institution tourists etc In the process of working up these patients we sometimes encounter parasite isolates that are useful for research We also can perform tests of cell-mediated immune function to evaluate how patients are responding to therapy In addition the protocol permits us to observe therapeutic responses to other drugs besides pentavalent antimony if necessary
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 79-I-0144 | None | None | None |